References
- Apoteket, Swedish Pharmaceutical Statistics 1998. Apoteket AB 1998.
- Kurata, JH, Norawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24: 2–17.
- Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160: 2093–9.
- Silverstein F, et al. Misoprostol reduces serious gastrointestinal complications in patient’s with reumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241–9.
- Griffin MR, Yared A, Ray WA, Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488–96.
- Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777–84.
- García Rodríguez LD. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:30–4.
- Antonov K, Isacson D. Prescription and nonprescription analgesics use in Sweden. Ann Pharmacother 1998;32:485–94.
- Langman MJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929–33.
- Talley N, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40:1345–50.
- Nyren O, Adami N-O, Gustavsson S. Social and economic effects of non-ulcer dyspepsia. Scand J Gastroenterol 1985;109 Suppl:41–7.
- Lanza LL, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995;155:1371–7.
- Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol Suppl 1996;102:3–8.
- Pincus T, Griffin M. Gastrointestinal disease associated with nonsteroidal antiinflammatory drugs: new insights from observational studies and functional status questionairs. Am J Med 1991;91:209–11.
- Wolfe M, Lichstenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99.
- Socialstyrelsen, E., Patientregistret. Vårddagar 1996. Stockholm: Socialstyrelsen (National Board on Health and Welfare). 1998.
- Landstingsförbundet. Kostnader per patient, vårddag, läkarbesök 1993. Stockholm: Landstingsforbundet (Federation of County Councils). 1995.
- SBU. Ont i magen-metoder för diagnos och behandling av dyspepsi, 2000, SBU. The Swedish Council on Technology Assessment in Health Care: Stockholm.
- Jo'nsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992;8: 234–44.
- Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149:1019–22.
- Bloom BS. Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy. Pharmacoeconomics 1992;1: 175–81.
- Moore R, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999;2:45–55.
- Stucki G, Johannesson M, Liang MH. Is misoprostol cost- effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994;154:2020–5.
- Jönsson B, Wahlqvist P. Management of nonsteroidal antiinflammatory drug-associated lesions: a cost-effectiveness perspective. Am J Med 1998;104:81S–8S.